Human Recombinant MIP-1 alpha (CCL3)

Macrophage inflammatory protein-1 alpha

More Views

From: 202 USD

Options

* Required Fields

Catalog # (Select a product)
Macrophage inflammatory protein-1 alpha
From: 202 USD

Overview

Macrophage inflammatory protein-1 alpha (MIP-1 alpha), also known as CCL3, is a member of the CC family of chemokines and is most closely related to CCL4 or MIP-1 beta. The two subtypes of human MIP-1 alpha (LD78α and LD78β) signal mainly through CCR5, which is the major coreceptor required for entry of certain strains of HIV-1 into permissive cells. MIP-1 chemokines are capable of inhibiting HIV-1 infection in susceptible cells. Also, chemokine receptors (CCR1 and CCR5) have been identified for LD78α, whereas three receptors (CCR1, CCR3, and CCR5) were reported for LD78β (Menten et al.). MIP-1 alpha exhibits a variety of proinflammatory activities in vitro, including leukocyte chemotaxis, and it inhibits the proliferation of hematopoietic stem cells in vitro and in vivo (Cook). In vitro experiments have shown that human MIP-1 alpha and beta have different attractant activities for subsets of immune effector cells, with human MIP-1 alpha having greater effects than human MIP-1 beta, particularly on CD8+ T cells and B cells. In addition to chemotaxis, MIP-1 alpha can also activate multiple cell types and induce cytokine production (Schall et al.).
Alternative Names:
AI323804, G0S19-1, LD78α, MIP-1a, SCYA3
Cell Type:
B Cells; Dendritic Cells; Mesenchymal Stem and Progenitor Cells; Monocytes; NK Cells; T Cells; T Cells, CD4+; T Cells, CD8+; Other
Species:
Human
Area of Interest:
Immunology; Stem Cell Biology
Molecular Weight:
7.8 kDa
Purity:
≥ 95%

Scientific Resources

Product Documentation

Educational Materials

(3)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Data

(A) The biological activity of Human Recombinant MIP-1 alpha (CCL3) was tested by its ability to mobilize Ca2+ using CHO cells transfected with human CCR5, the receptor of human CCL3. Ca2+ mobilization was measured using a fluorometric FLIPR® assay method. The EC50 is defined as the effective concentration of the growth factor at which Ca2+ mobilization is at 50% of maximum. The EC50 in the example above is less than 0.08 μg/mL. (B) 1 μg of Human Recombinant MIP-1 alpha (CCL3) was resolved with SDS-PAGE under reducing (+) conditions and visualized by Coomassie Blue staining. Human Recombinant MIP-1 alpha (CCL3) has a predicted molecular mass of 7.8 kDa.

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.